Loading cancer entity…
Loading cancer entity…
Clinical trials
6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02574078 | A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)(CheckMate370) | completed | Phase 1 / Phase 2 | 341 | Bristol-Myers SquibbINDUSTRY | 1 | May 6, 2021 | clinicaltrials |
| NCT03394118 | TAGRISSO (Osimertinib) in NSCLC Patients in Whom T790 Mutations Are Detected by Liquid Biopsy | completed | Phase 2 | 63 | Asan Medical CenterOTHER | 1 | Apr 27, 2021 | clinicaltrials |
| NCT01610336 | A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment | completed | Phase 2 | 161 | Novartis PharmaceuticalsINDUSTRY | 14 | Apr 8, 2021 | clinicaltrials |
| NCT03595644 | Maintenance Targeted Therapy With or Without Stereotactic Body Radiation Therapy for Stage IV Non-small Cell Lung Cancer | completed | Phase 2 | 74 | Tongji HospitalOTHER | 1 | Apr 8, 2021 | clinicaltrials |
| NCT01577654 | Phase 2 Study of EC145 Alone Versus EC145+Docetaxel Versus Docetaxel Alone in Participants With FR(++) 2nd Line Non Small Cell Lung Cancer(TARGET) | completed | Phase 2 | 203 | EndocyteINDUSTRY | 0 | Apr 1, 2021 | clinicaltrials |
| NCT02450903 | LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib. | completed | Phase 2 | 20 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 30, 2021 | clinicaltrials |
| NCT01967823 | T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer | completed | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Mar 24, 2021 | clinicaltrials |
| NCT02085070 | MK-3475 in Melanoma and NSCLC Patients With Brain Metastases | completed | Phase 2 | 65 | Yale UniversityOTHER | 1 | Mar 24, 2021 | clinicaltrials |
| NCT01066234 | Adjuvant CCRT vs CT in Minimal N2 NSCLC | completed | Phase 2 | 17 | Samsung Medical CenterOTHER | 1 | Mar 22, 2021 | clinicaltrials |
| NCT02747953 | Gilotrif (Afatinib) in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib | completed | Phase 2 | 50 | Samsung Medical CenterOTHER | 0 | Mar 19, 2021 | clinicaltrials |
| NCT02094573 | A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib | completed | Phase 2 | 222 | Ariad PharmaceuticalsINDUSTRY | 0 | Mar 15, 2021 | clinicaltrials |
| NCT03736837 | Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC(ALTER-L004) | completed | Phase 2 | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Mar 15, 2021 | clinicaltrials |
| NCT00606502 | Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment | completed | Phase 2 | 201 | Spectrum Pharmaceuticals, IncINDUSTRY | 6 | Mar 5, 2021 | clinicaltrials |
| NCT01820754 | Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC)(TOP1201 IPI) | completed | Phase 2 | 24 | Duke UniversityOTHER | 1 | Feb 26, 2021 | clinicaltrials |
| NCT03157089 | Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung(LUX-Lung-IO) | completed | Phase 2 | 24 | Boehringer IngelheimINDUSTRY | 5 | Feb 23, 2021 | clinicaltrials |
| NCT00219297 | Study of Patupilone in Patients With Brain Metastasis From Non-small Cell Lung Cancer | completed | Phase 2 | 50 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 21, 2021 | clinicaltrials |
| NCT01327612 | Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) | completed | Phase 2 | 12 | AmgenINDUSTRY | 3 | Feb 21, 2021 | clinicaltrials |
| NCT01945021 | Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC | completed | Phase 2 | 129 | PfizerINDUSTRY | 4 | Feb 21, 2021 | clinicaltrials |
| NCT01102231 | Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 106 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Feb 16, 2021 | clinicaltrials |
| NCT02577341 | Nimotuzumab Combined With Chemoradiotherapy for Unresectable Locally Advanced Squamous Cell Lung Cancer | completed | Phase 2 | 122 | Sun Yat-sen UniversityOTHER | 1 | Feb 11, 2021 | clinicaltrials |
| NCT01635270 | Phase 2 Study Evaluating Mid-position Strategy in Radiotherapy Treatment for Patients With a Locally Advanced Non-small Cell Lung Carcinoma(midP) | completed | Phase 2 | 54 | Centre Leon BerardOTHER | 1 | Feb 5, 2021 | clinicaltrials |
| NCT03044626 | Fostering Efficacy of Anti - PD-1 - Treatment: Nivolumab Plus Radiotherapy in Advanced NSCLC(FORCE) | completed | Phase 2 | 101 | AIO-Studien-gGmbHOTHER | 1 | Jan 13, 2021 | clinicaltrials |
| NCT01573702 | Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR) | completed | Phase 2 | 32 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jan 12, 2021 | clinicaltrials |
| NCT02574598 | MK-3475 in Combination With Docetaxel vs Docetaxel Alone in Non-Small Cell Lung Cancer Patients | completed | Phase 2 | 78 | Instituto Nacional de Cancerologia de MexicoOTHER | 1 | Jan 6, 2021 | clinicaltrials |
| NCT02082210 | A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer | completed | Phase 1 / Phase 2 | 97 | Eli Lilly and CompanyINDUSTRY | 1 | Dec 19, 2020 | clinicaltrials |
| NCT02308020 | A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain | completed | Phase 2 | 162 | Eli Lilly and CompanyINDUSTRY | 9 | Dec 19, 2020 | clinicaltrials |
| NCT02276027 | A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer | completed | Phase 2 | 66 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 16, 2020 | clinicaltrials |
| NCT01823068 | Vandetanib in Advanced NSCLC With RET Rearrangement | completed | Phase 2 | 17 | Samsung Medical CenterOTHER | 1 | Dec 7, 2020 | clinicaltrials |
| NCT00888511 | Tarceva And Radiotherapy in Locally Advanced Lung Cancer Non-small Cell Lung Cancer(TARLAL) | completed | Phase 2 | 15 | Olfred HansenOTHER | 1 | Nov 27, 2020 | clinicaltrials |
| NCT02730247 | Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 7 | Liza Villaruz, MDOTHER | 1 | Nov 19, 2020 | clinicaltrials |
| NCT00415363 | Study of Enzastaurin Versus Placebo in the Treatment of Patients With Brain Metastases of Lung Cancer, After Whole Brain Radiation Therapy | completed | Phase 2 | 109 | Eli Lilly and CompanyINDUSTRY | 5 | Nov 5, 2020 | clinicaltrials |
| NCT00723957 | A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Advanced Nonsmall-Cell Lung Cancer | completed | Phase 2 | 260 | R-PharmINDUSTRY | 10 | Oct 28, 2020 | clinicaltrials |
| NCT02785913 | Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches | completed | Phase 2 | 31 | SWOG Cancer Research NetworkNETWORK | 2 | Oct 23, 2020 | clinicaltrials |
| NCT00553254 | Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer | completed | Phase 2 | 55 | PfizerINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT01702844 | Single Arm on the Tolerability of Weekly Nab-paclitaxel | completed | Phase 2 | 42 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Oct 8, 2020 | clinicaltrials |
| NCT01532089 | Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations | completed | Phase 2 | 88 | Academic and Community Cancer Research UnitedOTHER | 1 | Oct 6, 2020 | clinicaltrials |
| NCT02879760 | Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients | completed | Phase 1 / Phase 2 | 16 | Turnstone Biologics, Corp.INDUSTRY | 1 | Oct 6, 2020 | clinicaltrials |
| NCT00835471 | 2nd Line Erlotinib Treatment With (Out) Chemotherapy of Advanced Non Small Cell Lung Cancer (NSCLC)(NVALT10) | completed | Phase 2 | 195 | Dutch Society of Physicians for Pulmonology and TuberculosisOTHER | 1 | Sep 29, 2020 | clinicaltrials |
| NCT01171170 | Paclitaxel-Carboplatin-Bevacizumab +/- Nitroglycerin in Metastatic Non-Squamous-Non-Small Cell Lung Cancer(NVALT12) | completed | Phase 2 | 223 | Dutch Society of Physicians for Pulmonology and TuberculosisOTHER | 1 | Sep 28, 2020 | clinicaltrials |
| NCT00950365 | Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer | completed | Phase 2 | 79 | Albert Einstein College of MedicineOTHER | 1 | Sep 16, 2020 | clinicaltrials |
| NCT03450330 | Assessing an Oral Janus Kinase Inhibitor, AZD4205, in Combination With Osimertinib in Patients Who Have Advanced Non-small Cell Lung Cancer(JACKPOT1) | completed | Phase 1 / Phase 2 | 10 | Dizal PharmaceuticalsINDUSTRY | 1 | Aug 24, 2020 | clinicaltrials |
| NCT01218516 | A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung | completed | Phase 2 | 130 | MorphotekINDUSTRY | 8 | Aug 20, 2020 | clinicaltrials |
| NCT03086733 | Phase II Lung Metcore - Preoperative Metformin for Lung Cancer(Metcore) | completed | Phase 2 | 28 | University Health Network, TorontoOTHER | 1 | Aug 19, 2020 | clinicaltrials |
| NCT02492568 | Pembrolizumab After SBRT Versus Pembrolizumab Alone in Advanced NSCLC(PEMBRO-RT) | completed | Phase 2 | 92 | The Netherlands Cancer InstituteOTHER | 1 | Aug 17, 2020 | clinicaltrials |
| NCT01833143 | Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D | completed | Phase 2 | 17 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 4, 2020 | clinicaltrials |
| NCT02490696 | Comparative Study of the Hypoxia Measured in FAZA and F-miso PET/CT Scan in Patients With Non-small Cell Lung Cancer(RTEP6) | completed | Phase 2 | 23 | Centre Henri BecquerelOTHER | 1 | Jul 30, 2020 | clinicaltrials |
| NCT00866970 | Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia | completed | Phase 2 | 124 | CSL BehringINDUSTRY | 9 | Jul 9, 2020 | clinicaltrials |
| NCT00530621 | Study of Enzastaurin Versus Placebo With Pemetrexed for Participants With Advanced or Metastatic Lung Cancer | completed | Phase 2 | 160 | Eli Lilly and CompanyINDUSTRY | 6 | Jul 1, 2020 | clinicaltrials |
| NCT01941654 | ATOM_local Ablative Therapy | completed | Phase 2 | 18 | Chinese University of Hong KongOTHER | 1 | Jun 18, 2020 | clinicaltrials |
| NCT01101334 | Study of Erlotinib With or Without Investigational Drug (CS-7017) in Subjects With Advanced Non-small Cell Lung Cancer | completed | Phase 2 | 90 | Daiichi SankyoINDUSTRY | 4 | Jun 16, 2020 | clinicaltrials |
Data updated 23 days agoSource updated May 6, 2021source: clinicaltrials